John Q. Adams Sr.

John Q Adams Sr

John Q. Adams, Sr., serves as president of J.Q. Enterprises, a holding company for his interests in real estate and ranching. During Mr. Adams’ long career in the pharmaceutical industry, he owned three companies: Baylor Laboratories, sold to Norwich Eaton Pharmaceuticals; Allerderm, Inc., sold to Virbac Inc., in France; and Adams Laboratories, a private pharmaceutical company focused on respiratory therapy, sold to Medeva Pharmaceuticals, where from 1991 to 1995, he served as President of Medeva Americas. Mr. Adams later repurchased Adams Laboratories from Medeva and served as its Chairman and Chief Executive Officer. Adams Laboratories changed its name to Adams Respiratory Therapeutics, and Mr. Adams served as Chairman of Adams Respiratory Therapeutics Inc. until October 14, 2005. He has been Vice Chairman of CereScan, Inc ., since June 2009 and its Director since March 2009.

Mr. Adams has served as a Director on several other Boards throughout his career, including Respirics, Inc., Adamis Pharmaceuticals Corporation, Medeva Americas, and Cellegy Pharmaceuticals Inc. He also retains memberships and board positions in several professional and philanthropic organizations, including the American College of Allergy and the Vanderbilt University Voice Center. In July 2007, he was elected to the Board of Trustees for Heidelberg College in Tiffin, Ohio, and in April 2009 he was inducted into the Hall of Excellence of the Ohio Foundation of Independent Colleges which each year honors three distinguished graduates from 34 Ohio colleges. He is also an Honorary Fellow of the American Academy of Otolaryngology-Head and Neck Surgery. Mr. Adams holds a degree in Biology from Heidelberg College.

Robert D. Casale

Robert D Casale

Robert D. Casale is a pharmaceutical industry veteran and currently serves as a Director on several Boards, including the Board of Directors for First Aid Shot Therapy, Novalere, and Insight Pharmaceuticals. Previously, Bob served as a Director for NextWave Pharmaceuticals, and he was Chairman of the Board of Directors for Topaz Pharmaceuticals, Inc.

Bob also co-founded Scerene Healthcare, Inc., in 2009 and served as its Chief Executive Officer. Prior to that, Bob served as COO of Adams Respiratory Therapeutics Inc., since October 2006. Bob served as Chief Development Officer, Chief Marketing Officer and Executive Vice President of Adams Respiratory Therapeutics from May 2005 to October 2006. Previously, Bob was Vice President, Business Development and Strategic Planning, for Pfizer, Inc., and he led development of a strategic plan for the newly merged Pfizer and Warner-Lambert consumer businesses.

Beginning in 1986, Bob served in many capacities at the former Warner-Lambert Company. Bob began his career at Warner-Lambert in their legal division, and later became lead counsel for Parke-Davis, the company's pharmaceutical business. He also served as lead counsel for the parent company on all acquisitions, merger, and licensing transactions. Subsequently, he was appointed Warner-Lambert's vice president of marketing for upper respiratory and gastrointestinal (GI) consumer products, including Benadryl®, Sudafed®, Zantac 75®, and Rolaids®. Bob also served as a Global Vice President for Warner-Lambert's GI and skin care businesses.

Bob received a bachelor's degree in business administration and English from Rutgers College in 1980 and a juris doctorate, with honors, from the Rutgers Law School in 1983.


Gene Colice

Gene Colice

Dr. Gene Colice is a practicing physician, serving as Director, Pulmonary Critical Care and Respiratory Services at Washington Hospital Center in Washington, D.C. In addition to his duties as a physician, Dr. Colice is also a Professor of Medicine at The George Washington University School of Medicine. He is a Fellow of the American College of Chest Physicians (ACCP) and a member of the American Thoracic Society (ATS). He is currently a member of the editorial board for Respiration and Chest. Dr. Colice has more than 300 publications, presentations and book chapters.

In addition to his medical practice and publications, Dr. Colice has worked in the pharmaceutical industry as a consultant to Adams Respiratory Therapeutics and was Director, Clinical Research at 3M Pharmaceuticals where he created clinical development plans, consistent with strategic business focus, to maximize commercial opportunity for respiratory products and to provide medically necessary safety and efficacy information.  He was responsible for preparation of all respiratory study protocols, regulatory filings and scientific manuscripts and for interpretation and analysis of all study data.  Specific projects included asthma products (inhaled beta-agonist bronchodilator and inhaled steroids) through NDA and worldwide approval and into Phase IV studies.

Dr. Colice received his medical degree from New York University Medical School in New York, NY, and performed his internship in Internal Medicine at New York University Medical Center, New York, NY, and his residency in Internal Medicine at Bellevue Hospital in New York, NY. He then completed a fellowship in Pulmonary and Critical Care Medicine at Yale-New Haven Medical Center in New Haven, Conn. Subsequently, he was a Professor of Medicine at the Dartmouth Medical School.